TrialAllergy2021
Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study.
Thomas Stranzl et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this paperpooled itcites it